Search clinical trials for: ALA

Total 254409 results

The Second Affiliated Hospital of Chongqing Medical...

Unknown

A Study of Switch From Nucleotide to Peginterferon Alfa-2a in CHB Patients Achieving HBeAg Loss and HBV DNA <200IU/ml (New Switch)

Chronic Hepatitis B

China
Johnson & Johnson Pharmaceutical Research & Development...
Ortho Biotech Products, L.P.

Completed

A Study to Evaluate the Hematologic Response Rate (the Rate at Which the Hemoglobin Level Rises) of PROCRIT (Epoetin Alfa) Given at a Dose of 80,000 Units Once Weekly to Cancer Patients With Anemia Who Are Receiving Chemotherapy.

Cancer | Anemia | Chemotherapy
Johnson & Johnson Pharmaceutical Research & Development...
Ortho Biotech Products, L.P.

Terminated

A Phase II Study to Assess Changes in Physical Function in Elderly Patients With Chronic Anemia

Anemia | Aged | Hemoglobins
Ortho Biotech Products, L.P.

Terminated

A Study to Assess Disability in Anemic Elderly Patients With Kidney Disease Receiving PROCRIT (Epoetin Alfa)

Kidney Diseases | Anemia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

The Effect of Epoetin Alfa on the Anemia of Patients With Multiple Myeloma

Multiple Myeloma | Anemia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study of the Safety and Efficacy of Long-term Correction of Anemia With Epoetin Alfa in Early Hemodialysis Patients

Anemia | Kidney Failure, Chronic
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Evaluate the Impact of Maintaining Hemoglobin Levels Using Epoetin Alfa in Patients With Metastatic Breast Cancer Receiving Chemotherapy

Quality of Life | Breast Neoplasms | Anemia
Ortho Biotech, Inc.

Completed

Effect of Epoetin Alfa on Hemoglobin, Symptom Distress, and Quality of Life in Patients Receiving Chemotherapy

Cancer | Anemia | Chemotherapy
Penn State University
California Walnut Commission

Completed

Effects of Walnuts on Central Blood Pressure, Arterial Stiffness Indices, Lipoproteins, and Other CVD Risk Factors

Cardiovascular Disease

United States
Amgen

Completed

Efficacy of Epoetin Alfa Deep Tank in Treatment of Anemia in Patients With Chronic Kidney Disease Receiving Hemodialysis

Nephrology
Ortho Biotech Products, L.P.

Withdrawn

Open-Label Extension Safety Study of PROCRIT in Patients With Anemia of Chronic Disease Due to Rheumatoid Arthritis

Rheumatoid Arthritis | Anemia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

PROCRIT Extended Dosing For Maintenance of Hemoglobin in Pre-Dialysis CKD Patients

Anemia | Renal Diseases

United States
Hoffmann-La Roche

Terminated

A Study Comparing Mircera and Epoetin Alfa for the Treatment of Anemia in Dialysis Patients With Chronic Kidney Disease.

Anemia

United States
Johnson & Johnson Pharmaceutical Research & Development...
Ortho Biotech Products, L.P.

Terminated

Treatment of Anemia in Diabetic Subjects With CKD

Anemia
Ortho Biotech Products, L.P.

Completed

An Open-Label Study to Evaluate the Effect of Every Other Week PROCRIT� (Epoetin Alfa) Dosing (40,000-60,000 Units) On Maintaining Quality of Life and Target Hemoglobin Levels in Anemic HIV-Infected Patients (CHAMPS II)

HIV Infections | Anemia
Janssen-Cilag B.V.

Completed

A Study of the Safety and Effectiveness of Epoetin Alfa on Hemoglobin Levels and Blood Transfusions in Cancer Patients Receiving Chemotherapy

Neoplasms | Anemia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

Epoetin Alfa for Anemia in Patients With Cancer Receiving Non-platinum Chemotherapy

Cancer | Anemia | Neoplasm
Janssen-Ortho Inc., Canada

Completed

A Safety and Efficacy Study for Epoetin Alfa in Pre-dialysis Subjects.

Anemia | Kidney Failure | Left Ventricular Hypertrophy
Amgen

Completed

Impact of Darbepoetin Alfa on Exercise Tolerance and Left Ventricular Structure in Subjects With Symptomatic Congestive Heart Failure (CHF) and Anemia

Anemia | Congestive Heart Failure
Third Affiliated Hospital, Sun Yat-Sen University
Peking University; Huazhong University of Science and Technology; First People... and other collaborators

Unknown

The Optimizing Treatment of Peginterferon (PEG IFN) Alpha in Chronic Hepatitis B Virus Patients With Low Level HBsAg

Chronic Hepatitis B

China
Amgen

Terminated

Epoetin Alfa (EPO) in Subjects With Chronic Kidney Disease (CKD)

Chronic Kidney Disease
Alma Lasers

Not yet recruiting

Safety and Efficacy Investigation on the Effects of ClearSkin Non-ablative ER:Glass 1540nm Laser Module in the Treatment of Acne Scars.

Acne Scars - Mixed Atrophic and Hypertrophic

Portugal
University of Melbourne

Recruiting

Improving Early Reperfusion With Adjuvant Dornase Alfa in Large Vessel Ischemic Stroke (EXTEND-IA DNase)

Ischemic Stroke

Australia
Alnylam Pharmaceuticals

Active, not recruiting

A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1)

Hypertension

United States, Canada, United Kingdom, Puerto Rico, Ukraine
National Cancer Institute (NCI)

Withdrawn

N-803 Alone or in Combination With BN-Brachyury Vaccine or Bintrafusp Alfa (M7824) for Participants With Castration Resistant Prostate Cancer

Castration Resistant Prostate Cancer

United States
Hospira, now a wholly owned subsidiary of Pfizer

Completed

Epoetin Alfa Biosimilar in the Management of Chemotherapy-Induced Symptomatic Anemia in Haematology and Oncology (ORHEO)

Solid Tumors | Lymphomas | Chemotherapy-induced Symptomatic Anemia | Malignant Hemopathies | Myelomas

France
Bioverativ, a Sanofi company

Completed

Safety, Efficacy and PK of BIVV001 in Pediatric Patients With Hemophilia A (XTEND-Kids)

Hemophilia A

Turkey, Australia, Canada, France, Germany, Hungary, Ireland, Italy, Netherlands, Spain, Sweden, Switzerland, Taiwan, United Kingdom, United States
Masonic Cancer Center, University of Minnesota

Completed

QUILT-3.033: Haplo NK With SQ ALT-803 for Adults With Relapsed or Refractory AML

Acute Myeloid Leukemia

United States
Astellas Pharma Inc
FibroGen

Completed

A Study of Intermittent Oral Dosing of ASP1517 in Hemodialysis Chronic Kidney Disease Patients With Anemia

Hemodialysis Chronic Kidney Disease Patients With Anemia

Japan
Wyeth is now a wholly owned subsidiary of Pfizer

Terminated

Study Evaluating The Efficacy And Safety Of Xyntha In Children Less Than 6 Years Of Age

Hemophilia A
Hospital General de Niños Pedro de Elizalde

Completed

Erythropoietin in Hemolytic Uremic Syndrome

Anemia | Hemolytic-Uremic Syndrome

Argentina
Novo Nordisk A/S

Completed

Efficacy and Safety of Turoctocog Alfa for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Chinese Patients With Haemophilia A (guardian TM 7)

Congenital Bleeding Disorder | Haemophilia A

China
2C Tech Corp

Completed

Intravitreal Injection of SeeQ CdSe 655 Alt Nanoparticles for Patients With Degenerative Retinal Diseases

Retinitis Pigmentosa

Mexico
Kissei Pharmaceutical Co., Ltd.
JCR Pharmaceuticals Co., Ltd.

Completed

A Phase III Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD)

Anemia

Japan
Alexion Pharmaceuticals

Completed

Post-approval Clinical Study of Asfotase Alfa Treatment for Patients With Hypophosphatasia (HPP) in Japan

Hypophosphatasia
Amgen

Withdrawn

Study to Evaluate Darbepoetin Alfa in Pediatric Subjects With Anemia Due to Chronic Kidney Disease

Anemia | Chronic Kidney Disease
Medical College of Wisconsin

Withdrawn

Erythropoietin Effects After Traumatic Brain Injury

Traumatic Brain Injury

United States
Bayer

Completed

A Phase 2/ 3 Trial to Evaluate the Efficacy and Safety of BAY86-6150

Hemophilia A, Hemophilia B

Italy, China, New Zealand, Russian Federation, Taiwan, Singapore, Bulgaria, United States, Denmark, Germany, Hungary, South Africa, United Kingdom, Romania, Colombia, Mexico, Turkey, France, India, Japan, Australia, Netherlands, Poland and more
Alios Biopharma Inc.

Completed

A Phase 2a Study to Evaluate ALS-008176 in the Virus Challenge Model

Respiratory Syncytial Virus Infections

United Kingdom
Amgen

Completed

Study of Transplant Related Anemia Treated With Aranesp® (STRATA)

Anemia
Synvista Therapeutics, Inc
Juvenile Diabetes Research Foundation

Terminated

Study of Alagebrium in Patients With Insulin-Dependent Type 1 Diabetes and Microalbuminuria

Diabetes Mellitus, Type 1 | Diabetic Nephropathy

Australia, Denmark
Amgen

Completed

Evaluating Aranesp® for the Treatment of Anemia in African-American Subjects With Chronic Renal Failure (CRF) Receiving Hemodialysis

Anemia | Chronic Renal Failure
University of Washington
Amgen

Completed

Study of Aranesp to Treat Anemia in Prostate Cancer Patients.

Anemia | Prostate Cancer

United States
Northwell Health
Olympus Corporation

Recruiting

Pilot Study Evaluating the Optimization of the ORBEYE Blue Light Filter During Fluorescence-Guided Resection of Gliomas

Malignant Glioma of Brain

United States
Sanofi

Recruiting

A Prospective Study to Observe & Describe Clinical Outcomes of Alglucosidase Alfa Treatment in Patients ≤6 Months of Age With Infantile-onset Pompe Disease (IOPD)

Glycogen Storage Disease Type II

Belgium, United States, Italy, Spain, Taiwan, United Kingdom, Netherlands, France, Germany
Ontario Clinical Oncology Group (OCOG)
Ortho Biotech, Inc.

Terminated

Epoetin Alfa in Advanced Non-Small Cell Lung Cancer (EPO-CAN-20)

Anemia | Lung Cancer | Non-Small-Cell Lung Carcinoma

Canada
Bioverativ, a Sanofi company

Active, not recruiting

Long-term Safety and Efficacy of Efanesoctocog Alfa (BIVV001) in Previously Treated Patients With Hemophilia A (XTEND-ed)

Hemophilia A

United States, Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, China, France, Germany, Greece, Hungary, Ireland, Italy, Japan, Korea, Republic of, Netherlands, Spain, Sweden, Switzerland, Taiwan, Turkey, United Kingdom
VA Office of Research and Development

Active, not recruiting

Mechanisms of EPO-induced Hypertension (EPIC)

Anemia | Chronic Kidney Disease | Blood Pressure

United States
Novo Nordisk A/S

Completed

Efficacy and Safety of Turoctocog Alfa Pegol (N8-GP) for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Chinese Patients With Haemophilia A (pathfinder10) (Pathfinder10)

Haemophilia A

China
AstraZeneca
Outcomes Insights

Completed

Andexanet Alfa and 4F-PCC Use in Patients Hospitalised With an Anticoagulant-related Major Bleed

Anticoagulant-related Major Bleed

United States

3

Subscribe